Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
MacroGenics
University of California, Davis
National Cancer Institute (NCI)
Tempus AI
Day One Biopharmaceuticals, Inc.
Incyte Corporation
Palleon Pharmaceuticals, Inc.
Incyte Corporation
MacroGenics
Memorial Sloan Kettering Cancer Center
NRG Oncology
NGM Biopharmaceuticals, Inc
Incyte Corporation
Seagen Inc.
Stanford University
Novartis
RECORDATI GROUP
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
GlaxoSmithKline
AstraZeneca
Pfizer
ADC Therapeutics S.A.
Exelixis
Pfizer
Eli Lilly and Company
NextCure, Inc.
Albert Einstein College of Medicine
Vanderbilt University Medical Center
Novartis
Rutgers, The State University of New Jersey
Incyte Corporation
Nektar Therapeutics
Nektar Therapeutics
Herlev Hospital
Ludwig Institute for Cancer Research
Ludwig Institute for Cancer Research
Incyte Corporation
Merck Sharp & Dohme LLC
Duke University
Pfizer
National Institutes of Health Clinical Center (CC)
Incyte Corporation
Pfizer
Bristol-Myers Squibb
Novartis
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Incyte Corporation
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)